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Background: The assumption that migrants acquire 
human immunodeficiency virus (HIV) before migra-
tion, particularly those from high prevalence areas, is 
common. Aim: We assessed the place of HIV acquisi-
tion of migrants diagnosed in four European countries 
using surveillance data. Methods: Using CD4+ T-cell 
count trajectories modelled to account for seroconver-
sion bias, we estimated infection year of newly HIV-
diagnosed migrants residing in the United Kingdom 
(UK), Belgium, Sweden and Italy with a known arrival 
year and CD4+ T-cell count at diagnosis. Multivariate 
analyses identified predictors for post-migration 
acquisition. Results: Between 2007 and 2016, migrants 
constituted 56% of people newly diagnosed with HIV 
in the UK, 62% in Belgium, 72% in Sweden and 29% in 
Italy. Of 23,595 migrants included, 60% were born in 
Africa and 70% acquired HIV heterosexually. An esti-
mated 9,400 migrants (40%; interquartile range (IQR): 
34–59) probably acquired HIV post-migration. This 
proportion was similar by risk group, sex and region 
of birth. Time since migration was a strong predictor 
of post-migration HIV acquisition: 91% (IQR: 87–95) 
among those arriving 10 or more years prior to diag-
nosis; 30% (IQR: 21–37) among those 1–5 years prior. 
Younger age at arrival was a predictor: 15–18 years 
(81%; IQR: 74–86), 19–25 years (53%; IQR: 45–63), 
26–35 years (37%; IQR: 30–46) and 36 years and older 
(25%; IQR: 21–33). Conclusions: Migrants, regardless 
of origin, sex and exposure to HIV are at risk of acquir-
ing HIV post-migration to Europe. Alongside accessible 
HIV testing, prevention activities must target migrant 
communities.
Introduction
Ca 22.3 million (4.4%) people living in the European 
Union (EU) today are non-EU citizens, of whom an 
estimated 2.4 million migrated to the EU in 2017 alone 
[1]. While most migrants are human immunodeficiency 
virus (HIV)-negative [2], a minority of migrants may be 
more vulnerable to HIV [3] because of an elevated prev-
alence in their country of origin. The European Centre 
for Disease Prevention and Control (ECDC) reported 
that more than two in five people diagnosed with HIV 
in 2018 in the EU/European Economic Area (EEA) were 
born outside the country in which they were diag-
nosed, with considerable variation across Europe [4]. It 
is often assumed migrants acquired HIV in their coun-
try of origin [5], particularly if prevalence is elevated 
in these settings. There is, however, growing evidence 
that people are at continued risk of acquiring HIV post-
migration [6]. This is mainly because sexual networks 
of migrants within destination countries may be largely 
confined to others from within the same community [6].
Understanding the probable timing of HIV acquisition 
in relation to migration is important to inform national 
prevention initiatives [7], but poses challenges. 
Previous studies attempted to assign a probable place 
and time of infection based upon assessment of self-
reported sexual history at diagnosis [5,8]. In isolation, 
these assessments are ambiguous because a person 
can have an undiagnosed HIV infection and/or may 
have multiple potential HIV exposures over many years. 
Furthermore, an individual may be unwilling to share or 
unable to remember their sexual behaviours, leading to 
uncertainties and recall biases [5,6].
To provide a population level estimate of post-migra-
tion acquisition and to address the ambiguities using 
clinical history, Public Health England (PHE) devel-
oped a novel method that applied routinely collected 
surveillance parameters (country of birth, year of 
arrival and CD4+ T-cell count at diagnosis) to averaged 
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time-modelled slopes of CD4+ T-cell decline. Using this 
method, Rice et al. estimated that 33% of heterosexu-
als born outside the United Kingdom (UK) and diag-
nosed with HIV between 2004 and 2010 acquired HIV 
after arrival into the UK [9], a figure three times greater 
than that based on clinical assessment. Similarly, 
Desgrees-du-Loû et al. applied a mixed method, includ-
ing both live-event questionnaires and modelling the 
CD4+ T-cell decline, to assign post-migration acquisition 
among Sub-Saharan Africans living in France [10]. The 
advancing migrant access to health services in Europe 
(aMASE) study used a similar approach combined 
with qualitative methods and estimated that 63% of 
migrants acquired infection post-migration across nine 
countries in Europe [11].
In the aforementioned studies, CD4+ T-cell trajectories 
were derived from the averages of multiple CD4+ T-cell 
counts taken from individuals for whom the serocon-
version date was approximately known. Then, the 
CD4+ T-cell count at diagnosis was applied against the 
modelled slopes to estimate infection length. However, 
CD4+ T-cell counts may temporarily decline during sero-
conversion [12], typically around 6 to 8 weeks follow-
ing exposure. Thus, CD4+ T-cell trajectories that include 
counts taken during seroconversion would flatten 
the slopes, underestimating the extent that migrants 
acquired HIV post-migration.
Here we estimate and compare the proportion of post-
migration HIV acquisitions within migrant communities 
diagnosed in four European countries (UK, Belgium, 
Sweden and Italy) using routinely collected surveillance 
data. We further refine PHE’s method to account for the 
bias from inclusion of samples taken from seroconvert-
ing individuals in the modelled CD4+ T-cell trajectories. 
A multivariate regression analysis is undertaken to 
identify predictors for post-migration HIV acquisition 




The ECDC HIV surveillance network invited all EU/EEA 
countries with HIV surveillance systems containing the 
required data fields to participate; the UK, Belgium, 
Sweden and Italy agreed. A 2-day workshop was held 
at PHE to discuss the project objectives. and agree 
on the final methodology before data collection and 
analyses.
Relevant surveillance information on all people diag-
nosed with HIV between 2007 and 2016 and reported to 
national HIV surveillance systems in the UK, Belgium, 
Sweden and Italy were gathered and analysed at PHE. 
All four countries provided the following: date of HIV 
diagnosis, CD4+ T-cell count at diagnosis (or within 91 
days of diagnosis), treatment status (treatment naive 
or treatment start date, to ensure CD4+ T-cell counts 
used in the analysis were extracted when people were 
treatment naive), age at diagnosis, sex and year of 
arrival into the destination country, country of birth 
and exposure category. Details of the national HIV 
surveillance systems in these countries have previ-
ously been described [13-18]. In our analyses, migrants 
were defined as individuals aged 15 years and older, 
born outside the country of diagnosis. Migrants were 
included if they had complete information on year of 
arrival in their destination country and a CD4+ T-cell 
count within 91 days of diagnosis.
To model CD4+ T-cell slopes following seroconversion, 
a separate dataset was created from the Swedish and 
UK surveillance data collections (this information was 
not available in Italy or Belgium). This dataset included 
1,653 people aged 15 years and older, irrespective of 
migrant status, who were diagnosed between 2000 
and 2014 with evidence of seroconversion (defined as 
a documented negative HIV test within 1 year of HIV 
diagnosis and at least two CD4+ T-cell measurements 
before starting treatment and/or death), as outlined in 
the Supplement.
Table 1
Migrants diagnosed with HIV in the United Kingdom, Belgium, Sweden and Italy, 2007–2016 (n = 23,595)
Population characteristics UK Belgium Sweden Italy
Year of HIV diagnosis 2007–16 2007–16 2007–16 2010–16
All HIV diagnoses (n, ≥ 15 years) 63,309 10,511 3,957 26,643
Migrant population n % n % n % n %
Total observed 32,892 4,979 2,785 7,658
Country of birth available 30,261 92 3,832 77 2,729 98 7,658 100
Reported CD4+ T-cell count at diagnosis 30,964 94 3,368 68 2,762 99 5,413 32
Reported year of arrival 21,888 66 3,734 75 1,653 59 1,543 20
Total eligiblea 17,856 54 2,635 53 1,634 59 1,470 19
HIV: human immunodeficiency virus; UK: United Kingdom
a Migrants eligible for this study had complete information on CD4+ T-cell count at HIV diagnosis and year of arrival.
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Table 2
Study population characteristics of migrants diagnosed with HIV infection in the United Kingdom, Belgium, Sweden and 
Italy, 2007–2016 (n = 23,595)
Characteristics
UK Belgium Sweden Italy
n % n % n % n %
Total eligible migrants 17,856 2,635 1,634 1,470
Age at diagnosis (years)
15–30 5,306 30 764 29 506 31 550 37
31–50 10,839 61 1,610 61 1,009 62 810 55
≥ 51 1,711 10 261 10 119 7 110 7
Age at arrival (years)
15–18 1,197 7 126 5 104 6 94 6
19–25 4,681 26 540 20 307 19 410 28
26–35 7,327 41 1,061 40 702 43 575 39
≥ 36 4,651 26 908 34 521 32 391 27
Exposure group
MSM 4,767 27 699 27 283 17 197 13
Het men 4,448 25 580 22 356 22 429 29
Het women 7,629 43 1,123 43 709 43 684 47
PWID men 277 2 34 1 28 2 48 3
PWID women 82 0 10 0 4 0 14 1
Blood-related products 274 2 102 4 20 1 18 1
First CD4+ T-cell count (cells/µl)
< 200 5,746 32 649 25 372 23 584 40
200–349 4,024 23 591 22 442 27 310 21
350–499 3,470 19 574 22 335 21 261 18
≥ 500 4,616 26 821 31 485 30 315 21
Region of birth 
Eastern Europe 1,225 7 136 5 57 3 244 17
Northern Europe 635 4 15 1 44 3 5 0
Southern Europe 1,342 8 159 6 46 3 70 5
Western Europe 462 3 221 8 16 1 6 0
Eastern Africa 5,733 32 368 14 701 43 57 4
Middle Africa 686 4 644 25 109 7 87 6
Northern Africa 105 1 77 3 23 1 83 6
Southern Africa 1,043 6 19 1 20 1 5 0
Western Africa 2,978 17 539 21 173 11 665 45
Latin America and Caribbean 1,517 8 232 9 82 5 188 13
Asia-Pacific 1,894 11 194 7 355 22 59 4
North America 236 1 20 1 8 0 0 0
Year of arrival
< 1983 419 2 51 2 48 3 16 1
1983–95 1,164 7 124 5 100 6 65 4
1996–99 1,159 6 76 3 25 2 73 5
2000–04 4,981 28 297 11 111 7 189 13
2005–09 5,113 29 777 29 483 30 292 20
2010–16 5,020 28 1,310 50 867 53 835 57
Year of diagnosis
2007 1,983 11 184 7 64 4 0 0
2008 2,020 11 214 8 90 6 0 0
2009 2,010 11 229 9 193 12 0 0
2010 1,895 11 298 11 219 13 123 8
2011 1,775 10 325 12 197 12 236 16
2012 1,588 9 314 12 174 11 272 19
2013 1,510 8 300 11 175 11 168 11
2014 1,703 10 257 10 216 13 204 14
2015 1,854 10 259 10 157 10 181 12
2016 1,518 9 255 10 149 9 286 19
Time between arrival and HIV diagnosis
Same year 3,667 21 1,023 39 740 45 554 38
1–5 years 6,353 36 998 38 556 34 456 31
6–10 years 4,265 24 298 11 145 9 205 14
> 10 years 3,571 20 316 12 193 12 255 17
Median age at diagnosis, years (IQR) 35 (23–43) 35 (29–43) 35 (29–41) 33 (27–41)
Median age at arrival, years (IQR) 29 (24–36) 31 (25–38) 31 (25–38) 29 (23–36)
Median time between arrival and diagnosis, years (IQR) 4 (1–9) 1 (0–5) 1 (0–5) 2 (0–8)
Median CD4+ T-cell count at diagnosis, cells/µl (IQR) 318 (148–507) 367 (201–557) 355 (205–534) 271 (100–458)
HIV: human immunodeficiency virus; Het: heterosexual; IQR: interquartile range; MSM: men who have sex with men; PWID: people who inject drugs; UK: United 
Kingdom.
Median CD4+ T-cell count taken within 91 days of HIV diagnosis.
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Estimation of seroconversion time with 
CD4+ T-cell trajectories
CD4+ T-cell slope trajectories (referred to as ‘the slope’) 
for people with known last negative and first positive 
HIV tests were built on the square root of CD4+ T-cell 
counts modelled through a maximum likelihood mul-
tilevel linear approach [19-23]. Since people in this 
cohort might present at the time of seroconversion, an 
‘anchor’ date 3 months after HIV diagnosis was set as 
the CD4+ T-cell count (where the person remained treat-
ment-naive) to remove the bias of capturing a serocon-
version-induced low CD4+ T-cell count (Supplement). 
Unlike previous studies that use the mid-point of HIV-
negative and -positive test dates, we modelled the 
slopes using counts reported from the anchor date 
onwards. The estimated CD4+ T-cell count at the anchor 
date was taken as the ‘intercept’. The follow-up period 
for each seroconverted individual was restricted to the 
point of treatment initiation, date of death or a 10-year 
period following diagnosis (for treatment naive people).
Potential predictors that could affect CD4+ T-cell tra-
jectories were identified as: sex, age, region of birth 
(Europe, Africa or other) and HIV exposure (men who 
have sex with men (MSM) contact, heterosexual con-
tact and other). For each predictor identified in a mul-
tivariable linear model, a specific CD4+ T-cell trajectory 
(slope, intercept and interquartile range (IQR)) was cal-
culated. Full methods and results from this model are 
detailed in the Supplement. The median time between 
the anchor date and the first CD4+ T-cell count was cal-
culated as follows:
t-median  (probable median interval between the 
anchor date and first CD4+ T-cell count)
where M  is the median of the intercept, and  S  is the 
slope.
Final formulae were adjusted for age group and region 
of birth subgroup (three groups were defined: Europe, 
Africa and other) to consider of the predictors associ-
ated with the slope and intercept (Supplement). The 
probable time of HIV infection for each person was 
then estimated to be t-median years before the first 
CD4+ T-cell count (IQR: +0.25 to +1.25 years around the 
estimated median time of HIV seroconversion).
Assigning post-migration acquisition
For each newly diagnosed individual, a period of HIV 
infection (defined as the IQR around the median) was 
estimated through the CD4+ T-cell trajectory formula 
using CD4+ T-cell count, age at diagnosis, and region 
of birth (formulae 1–3 in the  Supplement). Each per-
son was then classified into one of three categories: 
‘pre-migration’ HIV acquisition, ‘post-migration’ HIV 
acquisition or ‘undetermined’. Classification was 
done according to whether the period of HIV infection 
occurred before, after or within their reported year of 
arrival, respectively. Where there was ambiguity result-
ing from IQR, we assumed that people with a CD4+ T-cell 
count higher than the upper quartile limit belonged to 
the corresponding category ‘post-migration’ HIV acqui-
sition; people with a CD4+ T-cell count lower than the 
lower quartile limit were assumed to have acquired 
infection pre-migration. At the population level, upper 
and lower estimates of pre- and post-migration acquisi-
tion were generated; central estimates were produced 
through reassigning all ‘undetermined’ to either ‘post-‘ 
or ‘pre-migration’ based upon relative positioning of 
the median intercept. Migrants whose year of infec-
tion was the same as year of arrival were allocated as 
having acquired infection pre-migration. Where pre-
sented, years relate to year of diagnosis, and not year 
of infection.
Multivariate and statistical analyses
Predictors for acquiring HIV after migration were iden-
tified through logistic regression analyses. Factors 
that were found significant in univariate models were 
included in a multivariate model. An additional analy-
sis was undertaken to identify predictors for those 
acquiring HIV infection post-migration and had arrived 
1 to 5 years before HIV diagnosis.
Continuous variables were compared using the 
Wilcoxon–Mann–Whitney test. Rates were compared 
using the Pearson’s chi-squared test. The Cochran–
Armitage chi-squared trend test was used for time 
trend analyses. Bivariate and multivariable multilevel 
regression models were used to identify significant 
risk factors. Testing values and confidence intervals 
(CI) are at the 95% significance level. STATA (v13.0, 
StataCorp, College Station, Texas, United States) was 
used for analyses.
Ethical statement
Ethical approval was not needed since all information 
in the study was collected through routine national HIV 
surveillance.
Results
Modelling of CD4+ T-cell trajectories to 
estimate seroconversion
Overall, 1,653 people (≥ 15 years) with the last nega-
tive test and HIV diagnosis dates within one year (1,233 
from the UK and 420 from Sweden) were included in the 
CD4+ T-cell modelling, comprising a collective 15,881 
CD4+ T-cell counts (Supplement). Most of the 1,653 peo-
ple were MSM (81%) and born in Europe (84%), and 
two-thirds of people were diagnosed after 2005. The 
median interval between the last negative test and 
HIV diagnosis was 191 days (IQR: 105–271), and 11% of 
seroconverted individuals had a test interval of under 
2 months. The median time between HIV diagnosis and 
the first CD4+ T-cell count after the anchor date was 
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Table 3
Predictors of post-migration HIV acquisition among migrants diagnosed in the United Kingdom, Belgium, Sweden and 
Italy, 2007–2016 (n = 23,595)
Migrants (n)
Post-migration HIV acquisition 
% (IQR)
aOR (95% CI)
Total eligible 23,595 40 (34–59) –
Age at diagnosisa (years)
15–30 7,126 33 (26–43) NI
31–50 14,268 42 (36–51) NI
≥ 51 2,201 56 (52–61) NI
Age at arrival (years)
15–18 1,521 81 (74–86) 2.63 (2.18–3.15)
19–25 5,938 53 (45–64) 1.59 (1.44–1.76)
26–35 9,665 37 (30–45) 1.10 (1.01–1.20)
≥ 36 6,471 25 (21–49) Ref.
Exposure group
MSM 5,946 45 (41–53) 1.71 (1.53–1.92)
Het men 5,813 42 (36–51) 0.85 (0.78–0.93)
Het women 10,145 38 (31–47) Ref.
PWID men 387 30 (27–38) 0.94 (0.71–1.24)
PWID women 110 31 (25–38) 0.80 (0.60–1.06)
Blood related products 414 30 (27–37) 0.81 (0.64–1.02)
First CD4+ T-cell countb (cells/µl)
< 200 7,351 20 (15–27) NI
200–349 5,367 37 (28–49) NI
350–499 4,640 51 (41–65) NI
≥ 500 6,237 60 (57–63) NI
Region of birth
Eastern Europe 1,662 36 (31–46) 1.4 (1.14–1.72)
Northern Europe 699 46 (41–55) 1.65 (1.27–2.15)
Southern Europe 1,617 38 (34–46) 1.34 (1.07–1.66)
Western Europe 705 47 (43–55) 1.72 (1.31–2.26)
Eastern Africa 6,859 41 (33–50) 1.12 (0.95–1.31)
Middle Africa 1,526 29 (24–37) Ref.
Northern Africa 288 50 (42–56) 1.71 (1.17–2.48)
Southern Africa 1,087 43 (36–52) 1.52 (1.23–1.89)
Western Africa 4,355 38 (31–46) 1.31 (1.1–1.55)
Latin America and Caribbean 2,019 48 (43–56) 1.43 (1.17–1.76)
Asia-Pacific 2,502 43 (38–52) 1.14 (0.94–1.38)
Northern America 264 35 (33–41) 1.25 (0.82–1.90)
Year of arrival
< 1983 534 100 (no range) NIc
1983–1995 1,453 97 (95–99) NI
1996–1999 1,333 80 (73–87) NI
2000–2004 5,578 64 (52–74) NI
2005–2009 6,665 31 (24 –42) NI
2010–2016 8,032 11 (8–18) NI
Year of diagnosis
2007 2,231 37 (29–48) NIc
2008 2,324 38 (30–47) NI
2009 2,432 40 (32–50) NI
2010 2,535 43 (37–52) NI
2011 2,533 41 (35–50) NI
2012 2,348 41 (40–54) NI
2013 2,153 45 (38–51) NI
2014 2,380 44 (38–51) NI
2015 2,451 38 (33–43) NI
2016 2,208 36 (32–43) NI
Time between arrival and HIV diagnosisd
Same year 5,984 0 (no range) NA
1–5 years 8,363 30 (21–46) Ref.
6–10 years 4,913 63 (51–73) 4.23 (3.90–4.58)
> 10 years 4,335 91 (87–95) 23.11 (20.49–26.07)
aOR: adjusted odds ratio; HIV: human immunodeficiency virus; Het: heterosexual; IQR: interquartile range; MSM: men who have sex with men; NA: not available; 
NI: not included in regression analyses; PWID: people who inject drugs; Ref: reference.
a We used age at arrival in the multivariate regression model.
b First CD4+ T-cell count at diagnoses was not included in the regression model as it was not considered as a potential predictor for post-migration acquisition.
c Year of arrival and year of diagnosis were not included. Instead, we included the time between arrival and diagnosis.
d We assumed that people who were diagnosed in the same year of arrival acquired infection pre-migration.
6 www.eurosurveillance.org
141 days (IQR: 115–187); the median interval from the 
anchor date to end of follow-up was 3.7 years (IQR: 
1.5–7.0).
The median CD4+ T-cell count at the anchor date dif-
fered significantly by region of birth (p < 0.001); counts 
were 561, 438 and 543 cells/µL among those born in 
Europe, Africa and elsewhere, respectively. There was 
no relationship with age at diagnosis. Full results are 
provided in the Supplement.
The average decline in CD4+ T-cell count in the first year 
following seroconversion was 46, 65 and 67 cells/µL 
among those born in Europe, Africa and elsewhere, 
respectively. Each increase in year of age was asso-
ciated with a 1.3% increase in the rate of CD4+ T-cell 
decline (p = 0.002). Predictors were adjusted for in the 
final formulae (Supplement). No significant differences 
between MSM and heterosexual men and women were 
observed.
Population characteristics of HIV-diagnosed 
migrants
Migrants constituted 56% of people newly diagnosed 
with HIV in the UK, 62% in Belgium, 72% in Sweden 
and 29% in Italy between 2007 and 2016 (Table 1). 
Overall, 49% (23,595/48,314) of migrants diagnosed 
with HIV had available data and were included in our 
analyses. Completeness of information varied by coun-
try; the percentages of compete data from the UK, 
Belgium, Sweden and Italy were 54% (17,856/32,892), 
53% (2,635/4,979), 59% (1,634/2,785) and 19% 
(1,470/7,658), respectively.
In all four countries, ca 70% of the study population 
(16,517/23,595) was aged 30 years and above at diag-
nosis, and 68% (16,045) acquired HIV through het-
erosexual contact. Over 60% were African-born and 
more than half were diagnosed late (CD4+ T-cell count 
< 350 cells/µl) in the UK, Sweden, and Italy with 47% in 
Belgium (Table 2). The age distribution and CD4+ T-cell 
count at diagnosis among migrants included and 
excluded was broadly similar, however, migrant MSM, 
migrants from within the EU, and those who migrated 
more recently were slightly less likely to be included 
(Supplement).
Estimation of post-migration HIV acquisition
An estimated 40% (IQR: 34–59) of migrants acquired 
HIV post-migration. Of these, a similar proportion 
were European-born (40%; IQR: 36–49) or African-
born (39%; IQR: 32–48). This proportion was slightly 
higher among migrants born in Latin America and the 
Caribbean (48%; IQR: 43–56; Table 3). A similar propor-
tion of MSM (45%; IQR: 40–53) and heterosexual men 
(42%; IQR: 36–51) acquired infection post-migration. 
This proportion was slightly lower among heterosexual 
women (38%; IQR: 31–47). The highest percentage of 
migrants who acquired HIV post-migration was among 
those who had lived in the country of destination 
for ≥ 10 years (91%; IQR: 87–95), compared with 63% 
(IQR: 51–73) and 30% (IQR: 21–37) among those who 
Figure 1
Proportion of migrants who acquired HIV post-migration by destination country and year of diagnosis, United Kingdom, 
Belgium, Sweden, Italy, 2007–2016 (n = 23,595)
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Central estimate (%) 38 40 43 47 46 46 49 49 42 42












2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Central estimate (%) 26 28 29 28 28 31 32 33 32 27








Year of HIV diagnosis
B. Belgium
% migrants with 
HIV post-migration
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Central estimate (%) 31 28 25 30 28 23 27 29 11 21












2010 2011 2012 2013 2014 2015 2016
Central estimate (%) 47 31 33 52 38 32 20








Year of HIV diagnosis
D. Italy
% migrants with 
HIV post-migration
HIV: human immunodeficiency virus; UK: United Kingdom
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arrived between 6–10 years and 1–5 years ago, respec-
tively. A higher proportion of younger people (age at 
arrival) were estimated to have acquired the HIV infec-
tion in their country of destination: 15–18 years (81%; 
IQR: 74–86); 19–25 years (53%; IQR: 45–63); 26–35 
years (37%; IQR: 30–46); 36 years and older (25%; IQR: 
21–33) (Table 3). If the 5,985 individuals whose esti-
mated year of HIV acquisition was the same as their 
year of arrival were instead categorised as ‘post-migra-
tion HIV acquisition’, the proportion would increase 
from 40% to 65%.
United Kingdom
Overall, 44% (7,857/17,856; IQR: 37–53) of the migrants 
diagnosed between 2007 and 2016 had acquired HIV 
post-migration, increasing from 38% (754/1,983; IQR: 
30–49) in 2007 to 49% (826/1,703; IQR: 42–56) in 2014. 
The proportion dropped slightly to 42% (782/1,854; 
IQR: 37–50) in 2015 and 41% (635/1,518; IQR: 38–49) in 
2016 (10-year trend analysis: p < 0.05) (Figure).
 
From 2007–16, 45% (2,150/4,767; IQR: 41–53) of 
migrants who were MSM probably acquired HIV post-
migration. The absolute number (not adjusted for 
excluded migrants) more than doubled from 135 (IQR: 
123–174) in 2007 to 288 (IQR: 260–341) in 2015, while 
the percentage increased from 42% (IQR: 39–55) in 
2007 to 51% (IQR: 45–58) in 2011 and dropped to 38% 
(IQR: 35–45) in 2015. An estimated 228 MSM migrants 
to the UK probably acquired HIV post-migration in 2016. 
Overall, the proportion of heterosexual migrants who 
acquired HIV post-migration was 44% (IQR: 36–53) 
rising from 37% (IQR: 27–48) in 2007 to 47% in 2015 
and 2016. The number of heterosexual migrants who 
acquired HIV pre-migration decreased (1,586 in 2007 to 
449 and 358 in 2015 and 2016, respectively).
Belgium
An estimated 29% (764/2,635; IQR: 25–37) migrants 
acquired HIV post-migration, ranging between 26–31% 
over the period (Figure). The percentage and number of 
heterosexual migrants who acquired HIV post-migration 
increased from 26% (47/181) in 2007 to 32% (95/297) 
in 2013 and dropped slightly to 27% (70/259) in 2016 
(p value = 0.78). Among MSM migrants, the number 
(not adjusted for migrants excluded from the analysis) 
rose from 11 to 33 with a peak of 45 in 2013 and the 
corresponding percentage changed from 38% in 2007 
to 45% in 2013 and back to 38% in 2016 (p = 0.627).
Sweden
Overall, an estimated 25% (409/1,634; IQR: 22–33) 
migrants acquired HIV post-migration. Half of MSM 
migrants (138/283; IQR: 44–57) and 22% (239/1,065; 
IQR: 19–31) of heterosexual migrants acquired infec-
tion post-migration with no clear time trend.
Italy
An estimated 34% (IQR: 29–40) of 1,470 migrants 
acquired HIV post-migration. More than half of 
MSM migrants (111/197; 56%, IQR: 49–65) and 31% 
(342/1,113; IQR: 26–37) of heterosexual migrants 
acquired infection post-migration with no clear time 
trend.
Predictors for post-migration HIV acquisition
We included the following predictors in a bivariate anal-
ysis for post-migration HIV acquisition: age at arrival, 
risk-group, country of birth, year of arrival, year of diag-
nosis and time between migration and diagnosis.
Table 3  summarises the adjusted odds ratios (aOR) 
associated with post-migration HIV acquisition. People 
aged 15–18 years at arrival were more likely to have 
acquired HIV post-migration compared with those 
aged 36 years and older (aOR: 2.63; 95% CI: 2.18–3.15). 
MSM were more likely to acquire HIV post-migration 
(aOR: 1.71; 95% CI: 1.53–1.92) compared with (aOR: 
0.85; 95% CI: 0.78–0.93) heterosexual men. People 
who arrived 10 years or more before diagnosis were 23 
times more likely to acquire HIV post-migration (aOR: 
23.11; 95% CI: 20.49–26.07) compared with people 
who arrived within 5 years before diagnosis.
In a specific multivariate analysis of migrants who had 
recently arrived (1–5 years before diagnosis; 30% of 
study population), predictors of post-migration acqui-
sition included age at arrival (15–18 years (aOR: 2.43; 
95% CI: 1.80–3.28); 19–25 years (aOR: 1.63; 95% CI: 
1.43–1.86); 26–35 years (aOR: 1.18; 95% CI: 1.05–1.33); 
reference category: ≥ 36 years and sex between men 
(aOR: 1.63; 95% CI: 1.41–1.89) reference category: het-
erosexual women).
Discussion
We present multi-country estimates of post-migration 
HIV acquisition among 23,595 migrants diagnosed 
between 2007 and 2016 in Europe using a model para-
metrised by routinely collected surveillance data and 
adjusted for the potential effect of seroconversion. An 
estimated two in five migrants diagnosed with HIV in 
four European countries (UK, Belgium, Sweden and 
Italy) acquired HIV post-migration. While this propor-
tion increased with a longer time spent in the country of 
destination before HIV diagnosis, one in three migrants 
acquired HIV between 1 and 5 years before diagnosis 
after migration occurred. Our findings indicate that the 
public health response to HIV among migrant communi-
ties within Europe should be expanded from HIV testing 
strategies to also include primary prevention, targeting 
populations who have arrived relatively recently.
The ongoing risk of HIV acquisition after arrival among 
migrants from high HIV prevalence settings is per-
petuated by different factors. Regardless of country of 
origin, sexually active migrants are most likely to mix 
within their own communities [6]. For others, migra-
tion may change sexual behaviours. Some MSM may 
choose to migrate due to restrictive societal attitudes 
towards gay communities in their country of origin [24]. 
Nevertheless, migration to western Europe where HIV 
prevalence among the MSM community is high could 
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indicate that migrant MSM may be at risk of HIV acqui-
sition post-migration. It is important to note that the 
specific place of infection cannot be ascertained by 
our method since migrants do not necessarily migrate 
only once in a lifetime [25]. Furthermore, migrants may 
travel back and forth between their country of desti-
nation and country of origin. Regardless, it is critical 
to understand that migrants are at ongoing risk of HIV 
infection post-migration, and appropriate prevention 
services should be developed.
Over half of the migrants were diagnosed with a 
CD4+ T-cell count below 350 cells/µl. This indicates that, 
regardless of where HIV was acquired, migrant com-
munities may be particularly vulnerable to late diagno-
sis and consequently short-term mortality within one 
year of diagnosis and morbidity in addition to facilitat-
ing onward viral transmission. This situation is exac-
erbated in places where migrants are unaware of, or 
unfamiliar with, the national healthcare service [26], 
have language difficulties and/or because of stigma, 
both perceived or real, including the fear that migrants 
will be reported to the authorities [27]. It is not surpris-
ing that migrants who live longer in their destination 
country are more likely to acquire HIV post-migration. 
Further work is needed to ensure prevention services 
are available for all migrant populations, regardless of 
recency of arrival.
Our study has highlighted three important findings. 
Firstly, the risk of HIV acquisition post-migration is 
not limited to long-term residents; almost one in three 
migrants who were diagnosed 1–5 years after migra-
tion were estimated to have acquired HIV post-migra-
tion. Secondly, MSM as well as heterosexual migrants 
were at similarly high risk of acquiring HIV infection 
post-migration. Thirdly, while the risk of migrants from 
high prevalence countries acquiring HIV post-migration 
is higher, we show that migrants from within Europe 
are also at risk from acquiring HIV post-migration.
Overall, our estimates are in agreement with previ-
ously published studies [11] in Sweden [28] and Italy 
[29], and comparable to estimates among heterosexual 
migrants in the UK [9]. However, our study has sev-
eral new aspects, however. Compared with the aMASE 
study, our study is not reliant on a qualitative inter-
view, the population studied is 10-fold larger, and we 
include trend data and provide more accurate timing of 
infection through adjustment for seroconversion. Also 
in contrast to the other past studies, we have devel-
oped an approach that can be feasibly reproduced in 
many settings because the method relies on routinely 
collected surveillance data. We strongly recommend 
the routine collection of CD4+ T-cell count at diagnosis, 
country of birth and year of arrival to allow estimation 
of post-migration HIV acquisition across countries.
Our trend data indicate that the proportion of migrants 
who acquired HIV infection post-migration increased in 
the UK (from 38% in 2007 to 49% in 2014) and Belgium 
(from 26% in 2007 to 33% in 2014). The proportion 
dropped slightly in the 2 most recent years in both 
countries; this may be due to a decrease in HIV trans-
mission in MSM observed in both countries [30,31]. In 
addition, in the UK, the decline in post-migration acqui-
sition after 2014 could also be due to fewer migrants 
from high HIV prevalence countries (specifically from 
sub-Saharan Africa) arriving in the UK [32]. In Sweden 
and Italy, the number of HIV diagnoses among migrants 
increased over the past decade, despite a decreasing 
trend in the proportion acquired post-migration [4].
The uncertainties related to the application of 
CD4+ T-cell count at diagnosis to modelled slopes of 
CD4+ T-cell decline have been described previously 
[9,33]. A single CD4+ T-cell count cannot provide reliable 
information on the length of infection for an individual 
since CD4+ T-cell counts are affected by many factors 
including sleep [34], exercise [35], diet [36] and other 
infections [37]. However, our analysis is conducted 
at the population level so the extent of the variation 
becomes less apparent at this scale. Furthermore, our 
model represents an enhancement on previous meth-
ods. We used a large cohort of HIV-positive individuals 
(1,653) with 15,881 CD4+ T-cell counts; these data are 
unlikely to be replicable in the future with wide-scale 
adoption of treatment at diagnosis. The accuracy was 
enhanced further by restricting the inclusion criteria to 
people with a negative test within 1 year of diagnosis 
(compared with 3 years [22,23,38,39]).
To attenuate the impact of seroconversion [20] on 
CD4+ T-cell trajectories and to limit inherent bias in 
assuming that the seroconversion date is the mid-point 
of the HIV negative and positive dates, we applied an 
anchor date 3 months after diagnosis and included con-
secutive CD4+ T-cell counts thereafter. Our estimates 
of CD4+ T-cell trajectories fall within the range of pub-
lished models [20,22,23,37,38,40,41]. Nevertheless, 
interpretation should take the IQR into account.
CD4+ T-cell trajectories are only based on UK and 
Swedish data with an MSM cohort (diagnosed earlier 
than heterosexual people, on average). While MSM 
largely constituted the total number of seroconverted 
individuals, no significant differences were found in 
the median CD4+ T-cell count at the anchor date and 
in the decline by exposure, indicating that the slope 
can be considered representative for heterosexuals. 
Because of the comparatively small number of counts 
among people who inject drugs (PWID), this group was 
excluded from the analyses. While our model is still 
valid in countries with concentrated epidemics among 
PWID, the model would have to be specifically para-
metrised to PWID populations in these settings.
We took a conservative approach assigning the 5,984 
migrants whose infection was probably acquired in the 
same year as their arrival in the category of acquir-
ing infection pre-migration. If these individuals were 
instead assigned as acquiring infection post-migration, 
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the overall estimate of migrants with post-migration 
HIV acquisition would increase from 40% to 65%.
We excluded approximately half of the newly diagnosed 
migrants due to missing information. The completeness 
of the ‘year of arrival’ variable among migrants was 
around 70% in the UK, Belgium and Sweden and lower 
in Italy, which significantly increased over time to 76% 
in 2016. There were no major differences in the demo-
graphic or clinical characteristics of people included/
excluded from the analysis (Supplement). However, 
those excluded from the analysis were slightly more 
likely to be MSM, arrived more recently and had a 
higher CD4+ T-cell count at diagnosis; this indicates 
that we may be underestimating the proportion of peo-
ple acquiring HIV post-migration. Thus, we believe our 
estimates, especially estimates in more recent years, 
are applicable to the overall national reported migrant 
population.
While our method has largely attenuated the impact of 
seroconversion in the modelled CD4+ T-cell trajectories, 
it is possible that a small number of migrants were diag-
nosed during seroconversion; this potential bias would 
underestimate post-migration acquisition. However, 
the likelihood of migrants being diagnosed during sero-
conversion is low. A recent UK study found that only 
6% (108/1,728) of patients with a CD4+ T-cell count at 
diagnosis may feasibly have had their CD4+ T-cell count 
taken during seroconversion (based upon the last 
negative test and tests for recently acquired infection 
[42]). Potentially, other information can also help to 
assign the timing of infection in relation to migration, 
such as a previous negative HIV test date and primary 
infection. This information was not incorporated since 
only the UK and Sweden have information on previous 
HIV tests; of these, only a small proportion of migrants 
reported previous HIV negative tests. While the IQR 
around the estimate of post-migration acquisition indi-
cates the extent of uncertainty, it should not be inter-
preted as CI. The number and proportion of migrants 
who were first diagnosed in the country of birth before 
being diagnosed post-migration cannot be captured; 
such individuals are more likely to have been allocated 
as acquiring infection pre-migration if they had a low 
CD4+ T-cell count at presentation in their destination 
country. Alternatively, they could have been miscat-
egorised as post-migration if they received treatment 
before migration and if they had a low CD4+ T-cell count 
at diagnosis in the destination country. This may have 
’inflated’ the denominator and the proportion who 
acquired infection post-migration may be even higher. 
Finally, results may be affected by differential testing 
and screening policies for migrants in each setting.
Conclusion
Although the estimated proportion of post-migration 
HIV acquisition among migrants aged 15 years and 
older differed across countries and risk groups, our 
results deliver a consistent message that migrants are 
at continued risk of acquiring HIV infection after arrival 
to the destination country. We postulate that this is 
probably the case in other European countries where 
migrants from high HIV prevalence settings arrive 
and settle. Our findings underscore the need to target 
appropriate HIV prevention activities among migrant 
populations, regardless of recency of arrival, age and 
sexual orientation. Furthermore, HIV prevention mes-
sages aimed at migrants must be effectively tailored 
and delivered alongside HIV testing. The barriers to HIV 
testing, including language and cultural barriers, pov-
erty, affordability of testing, treatment and care regard-
less of residency status must be addressed for efforts 
to be effective.
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